We are live on ! Find out more
SAMH

Shanda Asset Management Holdings Portfolio holdings

AUM $2.09B
1-Year Est. Return 39.34%
This Fund
S&P 500
This Quarter Est. Return
-2.27%
1 Year Est. Return
+39.34%
3 Year Est. Return
+124.98%
5 Year Est. Return
-26.68%
10 Year Est. Return
+23.38%
AUM
$521M
AUM Growth
-$14.6M
Cap. Flow
+$205M
Cap. Flow %
39.39%
Top 10 Hldgs %
93.1%
Holding
46
New
13
Increased
4
Reduced
4
Closed
14

Top Buys

Rank Stock Value
1
HAPN
Happen Inc
HAPN
+$226M
2
NOAH
Noah Holdings
NOAH
+$1.59M
3
AMZN icon
Amazon
AMZN
+$927K
4
CLDR
Cloudera, Inc.
CLDR
+$138K

Top Sells

Rank Stock Value
1
KKR icon
KKR & Co
KKR
+$7.38M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$2.74M
3
EDIT icon
Editas Medicine
EDIT
+$2.56M
4
ALRM icon
Alarm.com
ALRM
+$1.47M
5
PTCT icon
PTC Therapeutics
PTCT
+$1.36M

Sector Composition

Rank Sector Weight
1 Financials 62.86%
2 Healthcare 19.74%
3 Miscellaneous 9.08%
4 Communication Services 6.41%
5 Consumer Discretionary 1.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMZN icon
26
PUT
Amazon
AMZN
$2.68T
$868K 0.17%
+10,000
New +$927K
CLDR
27
DELISTED
Cloudera, Inc.
CLDR
$773K 0.15%
87,300
+19,900
+30% +$138K
PRAH
28
DELISTED
PRA Health Sciences, Inc.
PRAH
$494K 0.09%
4,980
– –
LYFT icon
29
CALL
Lyft
LYFT
$5.94B
$408K 0.08%
10,000
-4,700
-32% -$257K
LH icon
30
Labcorp
LH
$26.3B
$389K 0.07%
2,698
– –
ICLR icon
31
Icon
ICLR
$13.3B
$368K 0.07%
2,499
– –
CRL icon
32
Charles River Laboratories
CRL
$13B
$292K 0.06%
2,207
– –
AXSM icon
33
Axsome Therapeutics
AXSM
$10.7B
– –
-19,958
Closed -$514K
CRSP icon
34
CRISPR Therapeutics
CRSP
$5.01B
– –
-58,158
Closed -$2.74M
EDIT icon
35
Editas Medicine
EDIT
$404M
– –
-103,579
Closed -$2.56M
NBIX icon
36
Neurocrine Biosciences
NBIX
$15.2B
– –
-10,000
Closed -$844K
NTLA icon
37
Intellia Therapeutics
NTLA
$1.59B
– –
-48,657
Closed -$797K
PTCT icon
38
PTC Therapeutics
PTCT
$5.48B
– –
-30,332
Closed -$1.36M
SGMO
39
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-114,410
Closed -$1.23M
SUPN icon
40
Supernus Pharmaceuticals
SUPN
$2.4B
– –
-10,000
Closed -$331K
VNDA icon
41
Vanda Pharmaceuticals
VNDA
$302M
– –
-44,787
Closed -$631K
TVRD
42
Tvardi Therapeutics
TVRD
$23.5M
– –
-1,527
Closed -$1.18M
ITCI
43
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-35,278
Closed -$458K
MRNS
44
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-2,500
Closed -$42K
ACOR
45
DELISTED
Acorda Therapeutics
ACOR
– –
-216
Closed -$199K
ZGNX
46
DELISTED
Zogenix, Inc.
ZGNX
– –
-10,000
Closed -$478K
1
2

Similar funds

OFS
OneAscent Financial Services Birmingham, Alabama $2.09B AUM 24.1% 1-Year Est. Return
IVAV
Index Venture Associates VI St. Helier, Channel Islands, Jersey $2.09B AUM 56.02% 1-Year Est. Return
RCA
Resonant Capital Advisors Madison, Wisconsin $2.09B AUM 20.07% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $2.09B AUM 34.27% 1-Year Est. Return
CCM
Cerberus Capital Management New York $2.1B AUM 36.72% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return
TFS
Thoroughbred Financial Services Brentwood, Tennessee $2.08B AUM 54.89% 1-Year Est. Return
WIC
Willis Investment Counsel Gainesville, Georgia $2.1B AUM 24.61% 1-Year Est. Return

Shanda Asset Management Holdings's Q3 2019 Portfolio in Review

As of Q3 2019, Shanda Asset Management Holdings held 46 positions worth $521M, down 2.7% from $536M the previous quarter. Its ten largest holdings account for 93% of the portfolio.

Shanda Asset Management Holdings deployed $205M of net new capital in Q3 2019, opening 13 new positions and adding to 4 existing holdings. Its largest new stake was Noah Holdings: 50,000 shares worth $1.46M.

By sector, the portfolio is most concentrated in Financials at 63% of assets, down from 74% a quarter earlier, followed by Healthcare and Miscellaneous.

On the sell side, the largest reduction was KKR & Co, an estimated $7.38M trimmed.

  • Shanda Asset Management Holdings's largest Q3 2019 buy was Noah Holdings: 50,000 shares worth $1.46M.
  • Shanda Asset Management Holdings added most to Happen Inc in Q3 2019, an estimated $226M increase.
  • Shanda Asset Management Holdings's biggest Q3 2019 reduction was KKR & Co, cutting an estimated $7.38M.
  • Shanda Asset Management Holdings fully exited CRISPR Therapeutics in Q3 2019, selling an estimated $2.74M.
  • Shanda Asset Management Holdings's ten largest holdings make up 93% of its $521M portfolio in Q3 2019.
  • Shanda Asset Management Holdings opened 13 new positions and closed 14 in Q3 2019.
  • Shanda Asset Management Holdings's portfolio value fell 2.7% quarter-over-quarter to $521M.

Based on Shanda Asset Management Holdings's 13F filing for Q3 2019, filed 14 Nov 2019.